LOS ANGELES, Jan. 15, 2015 (GLOBE NEWSWIRE) -- Response Genetics, Inc. (Nasdaq:RGDX), a company focused on the development and sale of molecular diagnostic tests that help determine a patient's response to cancer therapy, today announced that the company will present two abstracts at the upcoming American Society of Clinical Oncology Gastrointestinal (ASCO GI) Cancers Symposium in San Francisco, CA, January 15 to 17, 2015. One presentation, entitled "Expanded KRAS and NRAS assays increase detection of mutations that predict for resistance to therapy in colorectal cancer patients" demonstrates the clinical utility of Response Genetics' proprietary ResponseDX® KRAS and NRAS mutation detection tests in colorectal cancer. The other presentation, entitled "EGFR ligands and ERCC1 mRNA expression to predict clinical outcome in Japanese patients with metastatic colorectal cancer harboring overexpressed EGFR and KRAS exon 2 wild-type treated with cetuximab plus oxaliplatin-based chemotherapy (JACCRO CC-05/06 AR)" provides further clinical evidence for the company's patented ERCC1 mRNA expression technology in predicting response to chemotherapy.
"The innovative presentations at ASCO GI illustrate why ResponseDX® panels should be a first line choice among oncologists for patients" said Response Genetics' Chairman and Chief Executive Officer, Thomas A. Bologna. "As our RAS poster demonstrates, use of our expanded RAS assay identifies an additional 15% of tumors with mutations relative to assays restricted to RAS exon 2. We believe the expanded RAS testing offered by Response Genetics is invaluable in guiding therapy decisions for colorectal cancer patients."
Poster Session
Expanded KRAS and NRAS assays increase detection of mutations that predict for resistance to therapy in colorectal cancer patients
Date/Time: January 17, 2015, 7:00 – 7:55AM and 12:00 – 2:00PM, Location: Level 1, West Hall
EGFR ligands and ERCC1 mRNA expression to predict clinical outcome in Japanese (JPN) patients (pts) with metastatic colorectal cancer (mCRC) harboring overexpressed EGFR and KRAS exon 2 wild-type (KRAS wt) treated with cetuximab (cet) plus oxaliplatin-based chemotherapy (JACCRO CC-05/06 AR)
Date/Time: January 17, 2015, 7:00 – 7:55AM and 12:00 – 2:00PM, Location: Level 1, West Hall
About Response Genetics, Inc.
Response Genetics, Inc. (the "Company") is a CLIA-certified clinical laboratory focused on the development and sale of molecular diagnostic testing services for cancer. The Company's technologies enable extraction and analysis of genetic information derived from tumor cells stored as formalin-fixed and paraffin-embedded specimens. The Company's principal customers include oncologists and pathologists. In addition to diagnostic testing services, the Company generates revenue from the sale of its proprietary analytical pharmacogenomic testing services of clinical trial specimens to the pharmaceutical industry. The Company's headquarters is located in Los Angeles, California. For more information, please visit www.responsegenetics.com.
Forward-Looking Statement Notice
Except for the historical information contained herein, this press release and the statements of representatives of the Company related thereto contain or may contain, among other things, certain forward-looking statements, within the meaning of the Private Securities Litigation Reform Act of 1995.Such forward-looking statements involve significant risks and uncertainties. Such statements may include, without limitation, statements with respect to the Company's plans, objectives, projections, expectations and intentions, such as the ability of the Company, to provide clinical testing services to the medical community, to continue to strengthen and expand its sales force, to continue to build its digital pathology initiative, to attract and retain qualified management, to continue to strengthen marketing capabilities, to expand the suite of ResponseDX® products, to continue to provide the ResponseDX: Tissue of OriginTM test, the TC/PC pathology partnering program, the ResponseDX: Comprehensive Lung Profile, clinical trial support to pharmaceutical clients, to enter into new collaborations with pharmaceutical clients, to enter into areas of companion diagnostics, to continue to execute on its business strategy and operations, to continue to analyze cancer samples and the potential for using the results of this research to develop diagnostic tests for cancer, the usefulness of genetic information to tailor treatment to patients, and other statements identified by words such as "project," "may," "could," "would," "should," "believe," "expect," "anticipate," "estimate," "intend," "plan" or similar expressions.
These statements are based upon the current beliefs and expectations of the Company's management and are subject to significant risks and uncertainties, including those detailed in the Company's filings with the Securities and Exchange Commission. Actual results, including, without limitation, actual sales results, if any, or the application of funds, may differ from those set forth in the forward-looking statements. These forward-looking statements involve certain risks and uncertainties that are subject to change based on various factors (many of which are beyond the Company's control). The Company undertakes no obligation to publicly update forward-looking statements, whether because of new information, future events or otherwise, except as required by law.
Investor Relations Contact: Peter Rahmer Trout Group 646-378-2973 Company Contact: Thomas A. Bologna Chairman & Chief Executive Officer 323-224-3900
